Cruzersoftech
Seattle startup adyn raises $2.5M from 23andMe CEO and others for birth control prescription test
Health

Seattle startup adyn raises $2.5M from 23andMe CEO and others for birth control prescription test

Seattle startup raised a $2.5 million seed spherical co-led by Lux Capital and M13. The corporate plans to launch its flagship birth control optimization test later this yr and presently has a waitlist for early entry.

Adyn’s test analyzes hormone ranges to determine potential unwanted effects for girls — from pimples to blood clots — attributable to completely different strategies of birth control. The flagship product for customers will probably be an at-home test package; customers obtain information and personalised suggestions by means of adyn’s platform and telemedicine appointments. The corporate then sends prescriptions on to prospects.

The startup is led by founder , who got here up with the concept for adyn after she modified her birth control prescription and “was thrown into suicidal ideation.”

“Fortunately, I acknowledged this was because of the change in treatment,” mentioned Ruzzo, who has a Ph.D in genetics and genomics from Duke College.

The corporate says 52% of ladies attempt 4 or extra strategies of birth control earlier than discovering one which works.

Seattle startup adyn raises $2.5M from 23andMe CEO and others for birth control prescription test

Different members within the seed spherical embody Y Combinator, Ascend.VC, and Madrona Enterprise Group’s Pioneer Fund, an angel investor program . Particular person buyers reminiscent of 23andMe CEO Anne Wojcicki and Ashley Mayer of Glossier additionally participated.

Traders are pouring more money into girls’s digital well being startups, pushed partially by the pandemic and acceleration of digital well being providers, reported Monday.

“Each incentive you might presumably wish to serve the nicely being and well being of the feminine figuring out inhabitants, it’s acutely there,” mentioned , a managing director at Pioneer Sq. Labs, of 2025: Tomorrow, At the moment. “Whenever you’ve bought an space like that, that has simply been so traditionally, repeatedly and sustainably underserved, and under-invested over generations, that creates alternative.”

Related posts

COVID-19’s Impact on the Heart – An In-Depth Look

cruzer

New Decoy Protein Treatment Fools Coronavirus, Rendering It Impotent

cruzer

Healthcare giant Roche acquires Seattle DNA sequencing startup Stratos Genomics

cruzer